Clinical trials - Cancer Research SA

Filter By

BNT113 BIONTECH

Phase 2

Open and recruiting

Head and Neck

An open-label, controlled, multi-site, interventional, 2-arm, Phase II trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing programmed cell death ligand -1 (PD-L1) with combined positive score (CPS) ≥1.
Read more: Head and Neck
BIOATLA BA3701

Phase 1, Phase 2

Open and recruiting

Advanced or metastatic solid tumours – Bioatla

The objective of this study is to assess safety and efficacy of BA3071 in solid tumors
Read more: Advanced or metastatic solid tumours – Bioatla
BGB HNSCC

Phase 2

Open and recruiting

Head and Neck

This study is designed to evaluate the efficacy and safety of tislelizumab and tislelizumab in combination with investigational agent(s) in first-line recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Read more: Head and Neck
ATG-022 – SIV BOOKED 22FEB2023

Phase 1

Open and recruiting

Advanced or metastatic solid tumours

This is an Open, Multi-center, Phase I Clinical Study of ATG 022 in Patients with Advanced/metastatic Solid Tumors
Read more: Advanced or metastatic solid tumours
ASCENDIS 1L

Phase 1, Phase 2

Open and recruiting

Advanced or metastatic solid tumours – TransCon IL-2 β/γ

TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This is a first-in-human, open-label, Phase 1/2, dose escalation and dose expansion study of TransCon IL-2 β/γ as monotherapy or in combination therapy in adult participants with advanced or metastatic solid tumors. Given the unique PK profile…
Read more: Advanced or metastatic solid tumours – TransCon IL-2 β/γ
ARTISTRY 7

Phase 3

Open and recruiting

Ovarian – Platinum Resistant

This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator’s choice chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Read more: Ovarian – Platinum Resistant
AMT151

Phase 1

Open and recruiting

Advanced or metastatic solid tumours – AMT-151

This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-151, a novel antibody-drug conjugate against folate receptor alpha, in patients with selected advanced solid tumors.
Read more: Advanced or metastatic solid tumours – AMT-151
ARCUS EDGE

Phase 2

Open and recruiting

NSCLC Metastatic EDGE 1st line met

The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tolerability of immunotherapy-based combination therapy.
Read more: NSCLC Metastatic EDGE 1st line met
ACROIIMUNE. ONCOC4 part2

Phase 1

Open and recruiting

Advanced or metastatic solid tumours – AI-061

AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody. This is a dose escalation study to identify the maximum toxicity dose (MTD) or the recommended phase 2 dose (RP2D).
Read more: Advanced or metastatic solid tumours – AI-061